凤凰网首页 手机凤凰网

凤凰卫视
  • [亚太] 上证指数 2319.12 (1.00%) 深证成指 9466.14 1.78% 恒生指数 19664.10 -1.06% 台北 7233.69 0.17% 韩国 1964.83 0.39%
  • [亚太] 日经 8841.22 -0.09% 澳大利亚 4348.48 0.45% 新西兰 3294.64 0.40% 印度孟买 17234.00 0.92% 新加坡 2916.26 0.75%
  • [美洲] 道琼斯 12660.50 -0.58% 纳斯达克 2816.55 0.40% 标普500 1316.33 -0.16% 加拿大 12466.50 0.02% 巴西 62904.20 -0.08%
  • [欧洲] 英国富时 5733.45 -1.07% 法国CAC 3318.76 -1.32% 德国DAX 6511.98 -0.43% 俄罗斯 1508.04 -0.44% Stoxx50 2436.62 -0.97%
  • [其他] 纽约原油 99.70 0.00% 纽约黄金 1738.40 0.00% 人民币/美元 6.33 0.00% 美元指数 78.83 0.00% 基金指数 3782.30 1.37%
  • [亚太] 上证指数 2319.12 (1.00%) 深证成指 9466.14 1.78% 恒生指数 19664.10 -1.06% 台北 7233.69 0.17% 韩国 1964.83 0.39%
  • [亚太] 日经 8841.22 -0.09% 澳大利亚 4348.48 0.45% 新西兰 3294.64 0.40% 印度孟买 17234.00 0.92% 新加坡 2916.26 0.75%
  • [美洲] 道琼斯 12660.50 -0.58% 纳斯达克 2816.55 0.40% 标普500 1316.33 -0.16% 加拿大 12466.50 0.02% 巴西 62904.20 -0.08%
  • [欧洲] 英国富时 5733.45 -1.07% 法国CAC 3318.76 -1.32% 德国DAX 6511.98 -0.43% 俄罗斯 1508.04 -0.44% Stoxx50 2436.62 -0.97%
  • [其他] 纽约原油 99.70 0.00% 纽约黄金 1738.40 0.00% 人民币/美元 6.33 0.00% 美元指数 78.83 0.00% 基金指数 3782.30 1.37%
免费注册
华兰生物(002007)公告正文

华兰生物:2013年第三季度报告全文

公告日期 2013-10-29
股票简称:华兰生物 股票代码:002007
                华兰生物工程股份有限公司 2013 年第三季度报告全文华兰生物工程股份有限公司
    2013 年第三季度报告
      2013 年 10 月
                                                   华兰生物工程股份有限公司 2013 年第三季度报告全文
                                  第一节 重要提示
    公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整,不存在虚假记载、误导性陈述或者重大遗漏,并承担个别和连带的法律责任。
    所有董事均已出席了审议本次季报的董事会会议。
    公司负责人安康、主管会计工作负责人谢军民及会计机构负责人(会计主管人员)桑莉声明:保证季度报告中财务报表的真实、准确、完整。
                                                                      华兰生物工程股份有限公司 2013 年第三季度报告全文
                              第二节 主要财务数据及股东变化一、主要会计数据和财务指标公司是否因会计政策变更及会计差错更正等追溯调整或重述以前年度会计数据□ 是 √ 否
                                                                                               本报告期末比上年度末增减
                                       本报告期末                        上年度末
                                                                                                          (%)
    总资产(元)                                 3,492,896,749.04               2,962,677,475.26                         17.9%归属于上市公司股东的净资产
                                             2,948,075,763.46               2,597,709,723.70                        13.49%(元)
                                                        本报告期比上年同期                              年初至报告期末比上
                                     本报告期                                      年初至报告期末
                                                            增减(%)                                    年同期增减(%)
    营业收入(元)                       343,189,136.15                     45.5%          848,670,508.60               25.92%归属于上市公司股东的净利润
                                     119,575,446.51                    99.05%          350,571,619.76               49.37%(元)归属于上市公司股东的扣除非经
                                       97,596,256.59                   84.65%          310,222,547.73               41.96%常性损益的净利润(元)经营活动产生的现金流量净额
                                        --                       --                    289,744,306.69               80.15%(元)
    基本每股收益(元/股)                          0.2075                  99.14%                  0.6084               49.37%
    稀释每股收益(元/股)                          0.2075                  99.14%                  0.6084               49.37%
    加权平均净资产收益率(%)                       4.22%                   1.82%                  12.73%                3.22%非经常性损益项目和金额√ 适用 □ 不适用
                                                                                                                   单位:元
                           项目                                 年初至报告期期末金额                      说明
    非流动资产处置损益(包括已计提资产减值准备的冲销部分)                            64,221.06计入当期损益的政府补助(与企业业务密切相关,按照国家统
                                                                                8,830,086.81一标准定额或定量享受的政府补助除外)
    除上述各项之外的其他营业外收入和支出                                            -471,241.08
    其他符合非经常性损益定义的损益项目                                          41,913,721.95
    减:所得税影响额                                                                7,594,162.77
       少数股东权益影响额(税后)                                               2,393,553.94
    合计                                                                        40,349,072.03                   --对公司根据《公开发行证券的公司信息披露解释性公告第 1 号——非经常性损益》定义界定的非经常性损益项目,以及把《公
                                                                     华兰生物工程股份有限公司 2013 年第三季度报告全文开发行证券的公司信息披露解释性公告第 1 号——非经常性损益》中列举的非经常性损益项目界定为经常性损益的项目,应说明原因□ 适用 √ 不适用二、报告期末股东总数及前十名股东持股情况表
                                                                                                              单位:股
    报告期末股东总数                                                                                                  49,887
                                                 前 10 名股东持股情况
                                        持股比例                     持有有限售条件          质押或冻结情况
      股东名称               股东性质                 持股数量
                                         (%)                          的股份数量       股份状态          数量
    新乡市华兰生物技术      境内非国有法
                                          17.68%       102,723,822                   0
    有限公司                人
    新乡市金康生物科技      境内非国有法
                                          15.14%        87,961,115                   0
    开发有限公司            人
    香港科康有限公司        境外法人          13.24%        76,889,088                   0
    新乡市世辰生物技术      境内非国有法
                                           4.24%        24,604,400                   0
    有限公司                人中国工商银行-汇添
                        境内非国有法
    富均衡增长股票型证                          2.1%        12,196,542                   0
                        人券投资基金中国人民财产保险股
                        境内非国有法
    份有限公司-传统-                         1.35%         7,852,182                   0
                        人普通保险产品中国人民人寿保险股
                        境内非国有法
    份有限公司-分红-                         1.03%         5,999,958                   0
                        人个险分红中国工商银行-汇添
                        境内非国有法
    富医药保健股票型证                         0.86%         5,000,000                   0
                        人券投资基金正德人寿保险股份有
                        境内非国有法
    限公司-万能保险产                         0.81%         4,711,180                   0
                        人品中国农业银行-汇添
                        境内非国有法
    富社会责任股票型证                         0.69%         4,013,116                   0
                        人券投资基金
                                          前 10 名无限售条件股东持股情况
                                                                                                股份种类
             股东名称                         持有无限售条件股份数量
                                                                                         股份种类          数量
                                                             华兰生物工程股份有限公司 2013 年第三季度报告全文
    新乡市华兰生物技术有限公司                                        102,723,822 人民币普通股        102,723,822
    新乡市金康生物科技开发有限公司                                     87,961,115 人民币普通股         87,961,115
    香港科康有限公司                                                   76,889,088 人民币普通股         76,889,088
    新乡市世辰生物技术有限公司                                         24,604,400 人民币普通股         24,604,400中国工商银行-汇添富均衡增长股
                                                                   12,196,542 人民币普通股         12,196,542票型证券投资基金中国人民财产保险股份有限公司-
                                                                    7,852,182 人民币普通股          7,852,182传统-普通保险产品中国人民人寿保险股份有限公司-
                                                                    5,999,958 人民币普通股          5,999,958分红-个险分红中国工商银行-汇添富医药保健股
                                                                    5,000,000 人民币普通股          5,000,000票型证券投资基金正德人寿保险股份有限公司-万能
                                                                    4,711,180 人民币普通股          4,711,180保险产品中国农业银行-汇添富社会责任股
                                                                    4,013,116 人民币普通股          4,013,116票型证券投资基金
                                 上述第一、二、三、四股东存在关联关系,属于一致行动人。中国工商银行-汇添富上述股东关联关系或一致行动的说 均衡增长股票型证券投资基金、中国工商银行-汇添富医药保健股票型证券投资基金、
    明                               中国农业银行-汇添富社会责任股票型证券投资基金同为汇添富基金管理有限公司旗
                                 下基金。未知其他股东之间是否存在关联关系,是否属于一致行动人。参与融资融券业务股东情况说明
                                 无(如有)公司股东在报告期内是否进行约定购回交易□ 是 √ 否
                                                              华兰生物工程股份有限公司 2013 年第三季度报告全文
                                         第三节 重要事项一、报告期主要会计报表项目、财务指标发生重大变动的情况及原因报告期末,应收票据期末余额较期初余额减少45.08%,主要系票据到期结算所致。报告期末,应收账款期末余额较期初余额增加107.95%,主要系销售货物增加所致。报告期末,预付账款期末余额较期初余额增加44.05%,主要系预付平原新区启动区项目工程款增加所致。报告期末,其他应收款期末余额较期初余额减少98.50%,主要系土地保证金结算所致。报告期末,其他流动资产期末余额较期初余额增加60.76%,主要系银行理财产品增加所致。报告期末,长期股权投资期末余额较期初余额增加4,000万元,主要系投资华兰基因工程有限公司所致。报告期末,在建工程期末余额较期初余额增加72.21%,主要系平原新区启动区项目工程投入增加所致。报告期末,生产性生物资产期末余额较期初余额增加45.59%,主要系孙公司新乡市太行禽业有限公司购入鸡苗所致。报告期末,无形资产期末余额较期初余额增加53.98%,主要系土地使用权增加所致。报告期末,长期待摊费用期末余额较期初余额增加327万元,主要系电增容费等增加所致。报告期末,短期借款期末余额较期初余额增加14,000万元,主要系子公司华兰生物工程重庆有限公司增加借款所致。报告期末,预收账款期末余额较期初余额减少56.83%,主要系销售货物结算所致。报告期末,应交税费期末余额较期初余额增加392.01%,主要系税款未到缴纳期所致。本报告期,营业成本较上年同期增加35.79%,主要系子公司华兰生物工程重庆有限公司营业收入增加,相应营业成本增加所致。本报告期,营业税金及附加较上年同期减少37.98%,主要系一是本公司及下属单采血浆公司增值税征收方式变更为简易征收,即按6%计算缴纳增值税;二是子公司华兰生物疫苗有限公司上年同期确认甲型H1N1流感病毒裂解疫苗收入1.06亿元,而本报告期无此收入所致。本报告期,资产减值损失较上年同期增加659.46%,主要系子公司华兰生物疫苗有限公司部分疫苗产品计提跌价准备所致。本报告期,投资收益较上年同期增加86.68%,主要系理财产品收益增加所致。本报告期,营业外支出较上年同期减少90.33%,主要系本公司上年同期处置非流动资产损失较多所致。本报告期,经营活动产生的现金流量净额较上年同期增加80.15%,主要系一是银行存款利息收入增加;二是销售费用及税费等减少所致。本报告期,投资活动产生的现金流量净额较上年同期增加88.22%,主要系理财产品收益增加及平原新区项目影响所致。本报告期,筹资活动产生的现金流量净额较上年同期减少57.56%,主要系子公司华兰生物工程重庆有限公司归还到期借款所致。二、重要事项进展情况及其影响和解决方案的分析说明
    公司第五届董事会第二次会议审议通过了《华兰生物工程股份有限公司限制性股票激励计划草案》及及本次股权激励相关议案,向激励对象授予518万股限制性股票;公司将《股票期权激励计划(草案)》及相关材料报送至中国证券监督管理委员会(以下简称“证监会”), 并就有关事项与证监会进行了沟通。根据证监会的相关反馈意见,公司对限制性股票激励计划草案的部分内容进行了修订并报送证监会备案,7月3日,证监会对公司报送的《股票期权激励计划(草案)》确认无异议并进行了备案;公司第五届董事会第三次会议和2013年第一次临时股东大会审议通过了《华兰生物工程股份有限公司限制性股票激励计划草案修订稿》及本次股权激励相关议案,按照股东大会的授权,公司于2013年8月28日召开第五届董事会第五次会议审议通过了股权激励计划授予的相关事项,并于9月4日前收到激励对象新增股款人民币5,741.49万元,公司已于2013年9月13日办理完毕限制性股票登记手续,中国证券登记结算有限责任公司深圳分公司出具了《证券变更登记证明》。
                                                                华兰生物工程股份有限公司 2013 年第三季度报告全文三、公司或持股 5%以上股东在报告期内发生或以前期间发生但持续到报告期内的承诺事项
             承诺事项             承诺方                  承诺内容                  承诺时间    承诺期限   履行情况
    股改承诺                         不适用     不适用                                             不适用      不适用收购报告书或权益变动报告书中所
                                 不适用     不适用                                             不适用      不适用作承诺
    资产重组时所作承诺               不适用     不适用                                             不适用      不适用
                                            为避免同业竞争引起的损害本公司及其
                                            他股东利益,本公司实际控制人安康先
                                            生承诺:“作为本公司实际控制人期间,
                                 实际控制                                       2004 年 06                 正在严格
    首次公开发行或再融资时所作承诺              不在与本公司构成同业竞争的其他公司             长期有效
                                 人                                             月 25 日                   履行
                                            任职,在其经营业务中将不会利用其在
                                            本公司及本公司股东中的地位从事任何
                                            有损本公司及其他股东利益的行为。
                                            公司未来三年(2012-2014 年)的具体
                                            股东回报规划:1、公司可以采取现金、
                                            股票、现金与股票相结合或者法律、法
                                            规允许的其他方式分配利润。2、根据《公
                                            司法》等有关法律法规及《公司章程》
                                            的规定,在公司盈利且现金能够满足公
                                            司持续经营和长期发展、符合现金分红
                                            条件的前提下,2012-2014 年每年以现
                                            金方式分配的利润应不低于当年实现的
                                            可分配利润的 10%,且连续三年内以现
                                            金方式累计分配的利润不少于该三年实
                                            现的年均可分配利润的 30%。 3、未来 2012 年 08 2012-2014        正在严格
    其他对公司中小股东所作承诺       董事会
                                            三年(2012-2014 年)公司原则上每年 月 29 日        年度        履行
                                            度进行一次现金分红,公司董事会可以
                                            根据公司盈利情况及资金需求状况提议
                                            公司进行中期现金分红。 4、未来三年
                                            (2012-2014)公司可以根据累计可供分
                                            配利润、公积金及现金流状况,在保证
                                            最低现金分红比例和公司股本规模合理
                                            的前提下,为保持股本扩张与业绩增长
                                            相适应,公司可以采取股票股利方式进
                                            行利润分配,具体分红比例由公司董事
                                            会审议通过后,并提交股东大会审议决
                                            定。
    承诺是否及时履行                 是未完成履行的具体原因及下一步计
                                 无划(如有)
                                                              华兰生物工程股份有限公司 2013 年第三季度报告全文四、对 2013 年度经营业绩的预计2013 年度预计的经营业绩情况:归属于上市公司股东的净利润为正值且不属于扭亏为盈的情形归属于上市公司股东的净利润为正值且不属于扭亏为盈的情形2013 年度归属于上市公司股东的净利润变动幅
                                                                      40%     至                         60%度(%)2013 年度归属于上市公司股东的净利润变动区
                                                                   41,970.3   至                    47,966.06间(万元)
    2012 年度归属于上市公司股东的净利润(万元)                                                         29,978.79
                                            公司全资子公司华兰生物工程重庆有限公司,2013 年度营业收入及净利润业绩变动的原因说明
                                            较上年同期大幅增长。
                                                         华兰生物工程股份有限公司 2013 年第三季度报告全文
                                     第四节 财务报表一、财务报表1、合并资产负债表编制单位:华兰生物工程股份有限公司
                                                                                                    单位:元
                 项目                    期末余额                                期初余额流动资产:
    货币资金                                         984,947,082.38                          747,946,594.28
    结算备付金
    拆出资金
    交易性金融资产
    应收票据                                          33,346,715.00                           60,723,956.50
    应收账款                                         262,317,710.06                          126,142,394.44
    预付款项                                         124,513,235.35                           86,437,644.61
    应收保费
    应收分保账款
    应收分保合同准备金
    应收利息
    应收股利
    其他应收款                                           543,144.16                           36,318,582.57
    买入返售金融资产
    存货                                             334,220,116.96                          314,840,624.47
    一年内到期的非流动资产
    其他流动资产                                     674,700,000.00                          419,700,000.00
    流动资产合计                                        2,414,588,003.91                        1,792,109,796.87非流动资产:
    发放委托贷款及垫款
    可供出售金融资产
    持有至到期投资
    长期应收款
    长期股权投资                                      40,000,000.00
                              华兰生物工程股份有限公司 2013 年第三季度报告全文
    投资性房地产
    固定资产              781,492,712.57                        792,353,871.22
    在建工程               94,022,192.23                         54,598,402.95
    工程物资
    固定资产清理
    生产性生物资产          1,926,403.24                          1,323,158.53
    油气资产
    无形资产              137,641,616.60                         89,390,865.81
    开发支出
    商誉
    长期待摊费用            3,271,108.00
    递延所得税资产         19,954,712.49                         22,901,379.88
    其他非流动资产                                              210,000,000.00
    非流动资产合计           1,078,308,745.13                     1,170,567,678.39
    资产总计                 3,492,896,749.04                     2,962,677,475.26流动负债:
    短期借款              140,000,000.00
    向中央银行借款
    吸收存款及同业存放
    拆入资金
    交易性金融负债
    应付票据
    应付账款               43,110,972.00                         46,643,620.47
    预收款项                8,206,396.13                         19,008,932.61
    卖出回购金融资产款
    应付手续费及佣金
    应付职工薪酬              613,965.35                           236,307.19
    应交税费               35,484,312.60                        -12,151,945.83
    应付利息
    应付股利
    其他应付款             87,894,754.95                         78,101,742.24
    应付分保账款
    保险合同准备金
    代理买卖证券款
                                                              华兰生物工程股份有限公司 2013 年第三季度报告全文
    代理承销证券款
    一年内到期的非流动负债
    其他流动负债
    流动负债合计                                              315,310,401.03                          131,838,656.68非流动负债:
    长期借款
    应付债券
    长期应付款
    专项应付款
    预计负债
    递延所得税负债
    其他非流动负债非流动负债合计
    负债合计                                                  315,310,401.03                          131,838,656.68所有者权益(或股东权益):
    实收资本(或股本)                                   580,914,800.00                          576,204,800.00
    资本公积                                             344,042,132.03                          291,337,232.03
    减:库存股
    专项储备
    盈余公积                                             212,864,965.34                          212,864,965.34
    一般风险准备
    未分配利润                                          1,810,253,866.09                        1,517,302,726.33
    外币报表折算差额
    归属于母公司所有者权益合计                               2,948,075,763.46                        2,597,709,723.70
    少数股东权益                                         229,510,584.55                          233,129,094.88
    所有者权益(或股东权益)合计                             3,177,586,348.01                        2,830,838,818.58负债和所有者权益(或股东权益)总
                                                         3,492,896,749.04                        2,962,677,475.26计
    法定代表人:安康                     主管会计工作负责人:谢军民                         会计机构负责人:桑莉2、母公司资产负债表编制单位:华兰生物工程股份有限公司
                                                                                                         单位:元
                  项目                        期末余额                                期初余额
                                  华兰生物工程股份有限公司 2013 年第三季度报告全文流动资产:
    货币资金                  755,520,398.96                        488,811,604.84
    交易性金融资产
    应收票据                   14,471,440.00                         59,723,956.50
    应收账款                   37,910,256.86                         56,656,347.12
    预付款项                  103,234,236.90                         72,042,467.35
    应收利息
    应收股利
    其他应收款                128,487,942.37                         91,920,281.30
    存货                      185,618,247.40                        162,520,215.41
    一年内到期的非流动资产
    其他流动资产              300,000,000.00                        350,000,000.00
    流动资产合计                 1,525,242,522.49                     1,281,674,872.52非流动资产:
    可供出售金融资产
    持有至到期投资
    长期应收款                  5,379,060.00                          5,379,060.00
    长期股权投资              617,866,697.11                        577,866,697.11
    投资性房地产
    固定资产                  199,541,456.49                        205,822,776.19
    在建工程                   89,418,293.21                         35,769,064.09
    工程物资
    固定资产清理
    生产性生物资产
    油气资产
    无形资产                   65,655,723.98                         29,969,965.05
    开发支出
    商誉
    长期待摊费用                3,271,108.00
    递延所得税资产              3,797,456.54                          3,797,456.54
    其他非流动资产                                                   90,000,000.00
    非流动资产合计                984,929,795.33                        948,605,018.98
    资产总计                     2,510,172,317.82                     2,230,279,891.50流动负债:
                                        华兰生物工程股份有限公司 2013 年第三季度报告全文
    短期借款
    交易性金融负债
    应付票据
    应付账款                         26,841,025.54                         34,386,345.74
    预收款项                          1,392,347.00                           409,860.00
    应付职工薪酬                        401,448.03
    应交税费                         23,818,828.69                          6,553,319.77
    应付利息
    应付股利
    其他应付款                          709,139.05                           249,349.91
    一年内到期的非流动负债
    其他流动负债
    流动负债合计                         53,162,788.31                         41,598,875.42非流动负债:
    长期借款
    应付债券
    长期应付款
    专项应付款
    预计负债
    递延所得税负债
    其他非流动负债非流动负债合计
    负债合计                             53,162,788.31                         41,598,875.42所有者权益(或股东权益):
    实收资本(或股本)              580,914,800.00                        576,204,800.00
    资本公积                        352,789,929.54                        300,085,029.54
    减:库存股
    专项储备
    盈余公积                        212,864,965.34                        212,864,965.34
    一般风险准备
    未分配利润                     1,310,439,834.63                     1,099,526,221.20
    外币报表折算差额
    所有者权益(或股东权益)合计       2,457,009,529.51                     2,188,681,016.08
    负债和所有者权益(或股东权益)总   2,510,172,317.82                     2,230,279,891.50
                                                                华兰生物工程股份有限公司 2013 年第三季度报告全文计
    法定代表人:安康                         主管会计工作负责人:谢军民                       会计机构负责人:桑莉3、合并本报告期利润表编制单位:华兰生物工程股份有限公司
                                                                                                         单位:元
                   项目                           本期金额                              上期金额
    一、营业总收入                                               343,189,136.15                        235,866,861.21
       其中:营业收入                                        343,189,136.15                        235,866,861.21
             利息收入
             已赚保费
             手续费及佣金收入
    二、营业总成本                                               233,122,470.96                        181,388,491.28
       其中:营业成本                                        145,148,192.03                        106,728,570.29
             利息支出
             手续费及佣金支出
             退保金
             赔付支出净额
             提取保险合同准备金净额
             保单红利支出
             分保费用
             营业税金及附加                                    3,163,864.09                          3,761,521.57
             销售费用                                         33,745,227.38                         38,881,152.96
             管理费用                                         33,003,710.18                         33,657,169.42
             财务费用                                           340,923.64                          -5,297,083.34
             资产减值损失                                     17,720,553.64                          3,657,160.38
       加   :公允价值变动收益(损失以“-”号填列)
             投资收益(损失以“-”号
                                                              20,896,063.94                          7,583,037.33填列)
             其中:对联营企业和合营企业的投资收益
             汇兑收益(损失以“-”号填列)
    三、营业利润(亏损以“-”号填列)                           130,962,729.13                         62,061,407.26
                                                             华兰生物工程股份有限公司 2013 年第三季度报告全文
       加   :营业外收入                                    4,598,021.68                          2,226,176.25
       减   :营业外支出                                     246,175.81                           1,068,688.45
             其中:非流动资产处置损
                                                               19,956.32                           387,492.80失四、利润总额(亏损总额以“-”号填
                                                          135,314,575.00                         63,218,895.06列)
       减:所得税费用                                      16,181,415.84                          3,903,736.57
    五、净利润(净亏损以“-”号填列)                        119,133,159.16                         59,315,158.49
       其中:被合并方在合并前实现的净利润
       归属于母公司所有者的净利润                         119,575,446.51                         60,072,741.57
       少数股东损益                                          -442,287.35                           -757,583.08
    六、每股收益:                                    --                                    --
       (一)基本每股收益                                        0.2075                                0.1042
       (二)稀释每股收益                                        0.2075                                0.1042七、其他综合收益
    八、综合收益总额                                          119,133,159.16                         59,315,158.49
       归属于母公司所有者的综合收益
                                                          119,575,446.51                         60,072,741.57总额
       归属于少数股东的综合收益总额                          -442,287.35                           -757,583.08
    法定代表人:安康                      主管会计工作负责人:谢军民                       会计机构负责人:桑莉4、母公司本报告期利润表编制单位:华兰生物工程股份有限公司
                                                                                                      单位:元
                  项目                         本期金额                              上期金额
    一、营业收入                                              166,610,246.36                        148,031,712.91
       减:营业成本                                        54,524,939.04                         66,458,403.71
            营业税金及附加                                  1,409,393.94                          1,979,533.37
            销售费用                                        1,452,350.28                           147,101.87
            管理费用                                        8,845,286.32                         10,669,509.38
            财务费用                                       -2,275,774.86                         -3,677,602.04
            资产减值损失
       加:公允价值变动收益(损失以“-”号填列)
                                                               华兰生物工程股份有限公司 2013 年第三季度报告全文
           投资收益(损失以“-”号填
                                                             13,956,095.90                          5,843,174.19列)
           其中:对联营企业和合营企业的投资收益
    二、营业利润(亏损以“-”号填列)                          116,610,147.54                         78,297,940.81
       加:营业外收入                                           -44,183.62                             99,303.99
       减:营业外支出                                          171,564.15                            931,500.34
           其中:非流动资产处置损失                              10,641.32                           387,342.80三、利润总额(亏损总额以“-”号填
                                                            116,394,399.77                         77,465,744.46列)
       减:所得税费用                                        17,511,775.33                          4,453,876.98
    四、净利润(净亏损以“-”号填列)                           98,882,624.44                         73,011,867.48
    五、每股收益:                                      --                                    --
       (一)基本每股收益
       (二)稀释每股收益六、其他综合收益
    七、综合收益总额                                             98,882,624.44                         73,011,867.48
    法定代表人:安康                        主管会计工作负责人:谢军民                       会计机构负责人:桑莉5、合并年初到报告期末利润表编制单位:华兰生物工程股份有限公司
                                                                                                        单位:元
                 项目                            本期金额                              上期金额
    一、营业总收入                                              848,670,508.60                        673,968,499.22
       其中:营业收入                                       848,670,508.60                        673,968,499.22
             利息收入
             已赚保费
             手续费及佣金收入
    二、营业总成本                                              482,927,518.13                        384,036,436.09
       其中:营业成本                                       325,844,285.78                        239,957,214.04
             利息支出
             手续费及佣金支出
             退保金
             赔付支出净额
                                                 华兰生物工程股份有限公司 2013 年第三季度报告全文
             提取保险合同准备金净额
             保单红利支出
             分保费用
             营业税金及附加                     6,763,335.07                        10,904,789.60
             销售费用                          40,527,236.60                        53,021,788.26
             管理费用                         106,792,764.95                        93,543,355.56
             财务费用                         -19,922,790.30                       -16,409,014.41
             资产减值损失                      22,922,686.03                         3,018,303.04
       加   :公允价值变动收益(损失以“-”号填列)
             投资收益(损失以“-”号
                                               36,033,721.95                        19,302,413.80填列)
             其中:对联营企业和合营企业的投资收益
             汇兑收益(损失以“-”号填列)
    三、营业利润(亏损以“-”号填列)            401,776,712.42                       309,234,476.93
       加   :营业外收入                        9,016,663.54                         7,917,133.00
       减   :营业外支出                         593,596.75                          6,139,807.10
             其中:非流动资产处置损
                                                   32,003.52                         4,363,278.49失四、利润总额(亏损总额以“-”号填
                                              410,199,779.21                       311,011,802.83列)
       减:所得税费用                          63,246,669.78                        58,276,115.30
    五、净利润(净亏损以“-”号填列)            346,953,109.43                       252,735,687.53
       其中:被合并方在合并前实现的净利润
       归属于母公司所有者的净利润             350,571,619.76                       234,696,544.97
       少数股东损益                            -3,618,510.33                        18,039,142.56
    六、每股收益:                           --                                 --
       (一)基本每股收益                            0.6084                               0.4073
       (二)稀释每股收益                            0.6084                               0.4073七、其他综合收益
    八、综合收益总额                              346,953,109.43                       252,735,687.53
       归属于母公司所有者的综合收益
                                              350,571,619.76                       234,696,544.97总额
                                                               华兰生物工程股份有限公司 2013 年第三季度报告全文
       归属于少数股东的综合收益总额                          -3,618,510.33                         18,039,142.56
    法定代表人:安康                        主管会计工作负责人:谢军民                       会计机构负责人:桑莉6、母公司年初到报告期末利润表编制单位:华兰生物工程股份有限公司
                                                                                                        单位:元
                 项目                            本期金额                              上期金额
    一、营业收入                                                466,373,114.22                        469,661,469.80
       减:营业成本                                         159,278,827.21                        199,547,307.36
           营业税金及附加                                     3,905,559.57                          6,365,673.73
           销售费用                                           2,658,458.52                           365,985.52
           管理费用                                          27,488,627.65                         29,138,273.48
           财务费用                                         -24,602,201.80                        -13,923,619.51
           资产减值损失                                       1,017,871.01                           445,825.85
       加:公允价值变动收益(损失以“-”号填列)
           投资收益(损失以“-”号填
                                                             18,692,637.00                         10,789,745.83列)
           其中:对联营企业和合营企业的投资收益
    二、营业利润(亏损以“-”号填列)                          315,318,609.06                        258,511,769.20
       加:营业外收入                                          849,925.58                           1,507,391.58
       减:营业外支出                                          184,171.35                           5,842,489.24
           其中:非流动资产处置损失                              22,688.52                          4,276,849.56三、利润总额(亏损总额以“-”号填
                                                            315,984,363.29                        254,176,671.54列)
       减:所得税费用                                        47,450,269.86                         45,372,716.62
    四、净利润(净亏损以“-”号填列)                          268,534,093.43                        208,803,954.92
    五、每股收益:                                      --                                    --
       (一)基本每股收益
       (二)稀释每股收益六、其他综合收益
    七、综合收益总额                                            268,534,093.43                        208,803,954.92
    法定代表人:安康                        主管会计工作负责人:谢军民                       会计机构负责人:桑莉
                                                   华兰生物工程股份有限公司 2013 年第三季度报告全文7、合并年初到报告期末现金流量表编制单位:华兰生物工程股份有限公司
                                                                                            单位:元
               项目                  本期金额                              上期金额一、经营活动产生的现金流量:
    销售商品、提供劳务收到的现金               790,738,878.21                        855,789,785.72
    客户存款和同业存放款项净增加额
    向中央银行借款净增加额
    向其他金融机构拆入资金净增加额
    收到原保险合同保费取得的现金
    收到再保险业务现金净额
    保户储金及投资款净增加额
    处置交易性金融资产净增加额
    收取利息、手续费及佣金的现金
    拆入资金净增加额
    回购业务资金净增加额
    收到的税费返还                                                                     1,489,000.00
    收到其他与经营活动有关的现金                48,919,195.75                         32,492,583.38
    经营活动现金流入小计                            839,658,073.96                        889,771,369.10
    购买商品、接受劳务支付的现金               283,653,954.18                        261,755,151.07
    客户贷款及垫款净增加额
    存放中央银行和同业款项净增加额
    支付原保险合同赔付款项的现金
    支付利息、手续费及佣金的现金
    支付保单红利的现金
    支付给职工以及为职工支付的现
                                                 78,565,476.38                         70,440,290.20金
    支付的各项税费                             103,246,007.58                        150,779,926.50
    支付其他与经营活动有关的现金                84,448,329.13                        245,957,230.63
    经营活动现金流出小计                            549,913,767.27                        728,932,598.40
    经营活动产生的现金流量净额                      289,744,306.69                        160,838,770.70二、投资活动产生的现金流量:
                                         华兰生物工程股份有限公司 2013 年第三季度报告全文
       收回投资收到的现金             894,000,000.00                     2,693,218,888.90
       取得投资收益所收到的现金        36,033,721.95                        19,302,413.80
       处置固定资产、无形资产和其他
                                           64,500.00                           134,204.11长期资产收回的现金净额
       处置子公司及其他营业单位收到的现金净额
       收到其他与投资活动有关的现金
    投资活动现金流入小计                  930,098,221.95                     2,712,655,506.81
       购建固定资产、无形资产和其他
                                      134,891,576.24                        83,203,568.42长期资产支付的现金
       投资支付的现金                 659,000,000.00                     3,171,000,000.00
       质押贷款净增加额
       取得子公司及其他营业单位支付的现金净额
       支付其他与投资活动有关的现金   200,000,000.00
    投资活动现金流出小计                  993,891,576.24                     3,254,203,568.42
    投资活动产生的现金流量净额            -63,793,354.29                      -541,548,061.61三、筹资活动产生的现金流量:
       吸收投资收到的现金              57,414,900.00
       其中:子公司吸收少数股东投资收到的现金
       取得借款收到的现金             140,000,000.00                       100,000,000.00
       发行债券收到的现金
       收到其他与筹资活动有关的现金
    筹资活动现金流入小计                  197,414,900.00                       100,000,000.00
       偿还债务支付的现金             120,000,000.00
       分配股利、利润或偿付利息支付
                                       63,357,146.64                        66,877,909.33的现金
       其中:子公司支付给少数股东的股利、利润
       支付其他与筹资活动有关的现金
    筹资活动现金流出小计                  183,357,146.64                        66,877,909.33
    筹资活动产生的现金流量净额             14,057,753.36                        33,122,090.67四、汇率变动对现金及现金等价物的
                                          -25,160.33                           -44,621.63影响
    五、现金及现金等价物净增加额          239,983,545.43                      -347,631,821.87
                                                            华兰生物工程股份有限公司 2013 年第三季度报告全文
    加:期初现金及现金等价物余额                        744,501,536.95                         881,398,519.85
    六、期末现金及现金等价物余额                             984,485,082.38                         533,766,697.98
    法定代表人:安康                     主管会计工作负责人:谢军民                       会计机构负责人:桑莉8、母公司年初到报告期末现金流量表编制单位:华兰生物工程股份有限公司
                                                                                                       单位:元
               项目                           本期金额                              上期金额一、经营活动产生的现金流量:
    销售商品、提供劳务收到的现金                        556,533,226.52                         642,449,331.89
    收到的税费返还                                                                                 703,000.00
    收到其他与经营活动有关的现金                         28,698,108.20                          20,555,003.68
    经营活动现金流入小计                                     585,231,334.72                         663,707,335.57
    购买商品、接受劳务支付的现金                        182,466,477.43                         165,545,523.53
    支付给职工以及为职工支付的现
                                                          25,343,229.05                          21,711,792.32金
    支付的各项税费                                       63,107,832.61                          89,821,151.55
    支付其他与经营活动有关的现金                         29,384,410.25                         182,660,586.73
    经营活动现金流出小计                                     300,301,949.34                         459,739,054.13
    经营活动产生的现金流量净额                               284,929,385.38                         203,968,281.44二、投资活动产生的现金流量:
    收回投资收到的现金                                  695,000,000.00                        2,018,840,000.00
    取得投资收益所收到的现金                             18,692,637.00                          10,789,745.83
    处置固定资产、无形资产和其他
                                                            214,500.00                            2,743,640.46长期资产收回的现金净额
    处置子公司及其他营业单位收到的现金净额
    收到其他与投资活动有关的现金
    投资活动现金流入小计                                     713,907,137.00                        2,032,373,386.29
    购建固定资产、无形资产和其他
                                                          84,913,942.44                          64,362,732.57长期资产支付的现金
    投资支付的现金                                      595,000,000.00                        2,460,000,000.00
    取得子公司及其他营业单位支付的现金净额
    支付其他与投资活动有关的现金                         49,000,000.00
                                                            华兰生物工程股份有限公司 2013 年第三季度报告全文
    投资活动现金流出小计                                    728,913,942.44                        2,524,362,732.57
    投资活动产生的现金流量净额                               -15,006,805.44                        -491,989,346.28三、筹资活动产生的现金流量:
       吸收投资收到的现金                                57,414,900.00
       取得借款收到的现金                                                                      100,000,000.00
       发行债券收到的现金
       收到其他与筹资活动有关的现金
    筹资活动现金流入小计                                     57,414,900.00                         100,000,000.00
       偿还债务支付的现金
       分配股利、利润或偿付利息支付
                                                         57,620,480.00                              66,877,909.33的现金
       支付其他与筹资活动有关的现金
    筹资活动现金流出小计                                     57,620,480.00                              66,877,909.33
    筹资活动产生的现金流量净额                                 -205,580.00                              33,122,090.67四、汇率变动对现金及现金等价物的
                                                             -25,148.49                                -43,369.66影响
    五、现金及现金等价物净增加额                            269,691,851.45                         -254,942,343.83
       加:期初现金及现金等价物余额                     485,366,547.51                             704,108,696.11
    六、期末现金及现金等价物余额                            755,058,398.96                         449,166,352.28
    法定代表人:安康                      主管会计工作负责人:谢军民                       会计机构负责人:桑莉二、审计报告第三季度报告是否经过审计□ 是 √ 否公司第三季度报告未经审计。
                                                                          华兰生物工程股份有限公司
                                                                               董事长:安康
                                                                             2013 年 10 月 29 日
数据加载中...
prevnext
手机查看股票